A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Clinical trial NCT04622319 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04622319
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-04
- Primary completion
- 2025-07-02
- Enrollment
- 1600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.